Results of the percent recovery study.

<p>Results of the percent recovery study.</p

Shows plots of RBP4 control and calibrator samples analyzed by MSIA.

<p>Samples ranged in concentration from 7.06 to 500 ug/mL (0.30 to 24.31 nmol/mL) and the data represents the results obtained over an eleven day period.</p

Is a comparison between quantitative MSIA and the Immun Diagnostik ELISA for RBP4.

<p>A) RBP4 concentrations (ug/mL) obtained by both methods were compared by same-scale Passing & Bablok regression (solid black line). The dashed lines are the 95% confidence interval. B) The Altman-Bland test determined that the overall bias of the MSIA to be 1.195 (solid black line). The dashed lines represent the 95% limit of agreement.</p

Are the plotted results of the quantitative MSIA linearity study.

<p>The regression analysis was only able to fit a first order polynomial (1.087+3.1016×; R² = 0.990) to the data set. The absence of non-linearity describes the assay as possessing linear characteristics.</p

Shows representative MS traces of RBP4 acquired during the method comparison study.

<p>The normalized mass spectra display a wide variety of RBP4 variation found in human plasma.</p

Intra-and inter-assay precision.

<p>Intra-and inter-assay precision.</p

Assay linearity.

<p>Assay linearity.</p

MS/MS transitions for IGF1 and LR3-IGF1 used for the quantification.

<p>MS/MS transitions for IGF1 and LR3-IGF1 used for the quantification.</p

Spiking recovery.

<p>Spiking recovery.</p

Representative standard curve for the IGF1 SRM-MSIA.

<p>Plotted are the peak area ratios of IGF1/LR3-IGF1 over the standards concentrations. Solid line: linear fit with R² = 0.999, SEE = 0.135. Dotted lines: 95% prediction intervals.</p